CN101970662A - 带有修饰碱基的寡核苷酸作为抗病毒剂的应用 - Google Patents

带有修饰碱基的寡核苷酸作为抗病毒剂的应用 Download PDF

Info

Publication number
CN101970662A
CN101970662A CN2008801234555A CN200880123455A CN101970662A CN 101970662 A CN101970662 A CN 101970662A CN 2008801234555 A CN2008801234555 A CN 2008801234555A CN 200880123455 A CN200880123455 A CN 200880123455A CN 101970662 A CN101970662 A CN 101970662A
Authority
CN
China
Prior art keywords
modified
compound
oligonucleotide
nucleobases
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801234555A
Other languages
English (en)
Chinese (zh)
Inventor
马特·萨尔玛
安德烈斯·梅利茨
马蒂·卡拉尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baltic Technology Development Ltd
Original Assignee
Baltic Technology Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baltic Technology Development Ltd filed Critical Baltic Technology Development Ltd
Publication of CN101970662A publication Critical patent/CN101970662A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2008801234555A 2007-11-05 2008-11-05 带有修饰碱基的寡核苷酸作为抗病毒剂的应用 Pending CN101970662A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98554807P 2007-11-05 2007-11-05
US60/985,548 2007-11-05
US5768508P 2008-05-30 2008-05-30
US61/057,685 2008-05-30
PCT/FI2008/050633 WO2009060122A2 (en) 2007-11-05 2008-11-05 Use of oligonucleotides with modified bases as antiviral agents

Publications (1)

Publication Number Publication Date
CN101970662A true CN101970662A (zh) 2011-02-09

Family

ID=40551515

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801234555A Pending CN101970662A (zh) 2007-11-05 2008-11-05 带有修饰碱基的寡核苷酸作为抗病毒剂的应用

Country Status (10)

Country Link
US (1) US20110171287A1 (cg-RX-API-DMAC7.html)
EP (1) EP2212420A2 (cg-RX-API-DMAC7.html)
JP (1) JP5710977B2 (cg-RX-API-DMAC7.html)
CN (1) CN101970662A (cg-RX-API-DMAC7.html)
AU (1) AU2008324066A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0819191A2 (cg-RX-API-DMAC7.html)
CA (1) CA2704549A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010004983A (cg-RX-API-DMAC7.html)
WO (1) WO2009060122A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003234B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069551A (zh) * 2014-08-19 2021-07-06 西北大学 蛋白质/寡核苷酸核-壳纳米颗粒治疗剂

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704560A1 (en) * 2007-11-05 2009-05-14 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009144365A1 (en) * 2008-05-30 2009-12-03 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
NZ601784A (en) 2010-03-08 2014-08-29 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
BR112014005951A2 (pt) 2011-09-13 2017-04-04 Monsanto Technology Llc métodos e composições para controle de erva daninha
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
AU2012308686B2 (en) 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
EP2756086B1 (en) 2011-09-13 2018-02-21 Monsanto Technology LLC Methods and compositions for weed control
BR112014005963A2 (pt) 2011-09-13 2020-12-08 Monsanto Technology Llc métodos de controle de planta, de redução de expressão de um gene als em uma planta, de identificação de polinucleotídeos úteis na modulação de expressão do gene als, de fazer um polinucleotídeo, composições compreendendo um polinucleotídeo e um agente de transferência ou um herbicida, cassete de expressão microbiana, bem como molécula de polinucleotídeo
WO2013040117A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
AU2012308753B2 (en) 2011-09-13 2018-05-17 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
EP2855680B8 (en) 2012-05-24 2020-04-15 Monsanto Technology LLC Compositions and methods for silencing gene expression
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014047653A2 (en) 2012-09-24 2014-03-27 Seminis Vegetable Seeds, Inc. Methods and compositions for extending shelf life of plant products
US10077451B2 (en) 2012-10-18 2018-09-18 Monsanto Technology Llc Methods and compositions for plant pest control
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
FR2997705B1 (fr) * 2012-11-08 2015-10-16 Nicolas Ugolin Nucleotide 3' bloquant la traduction des proteines (sasb)
AU2013371825B2 (en) 2013-01-01 2019-10-24 A.B. Seeds Ltd. Methods of introducing dsRNA to plant seeds for modulating gene expression
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
CA2897458A1 (en) 2013-01-15 2014-07-24 Monsanto Technology Llc Methods and compositions for plant pest control
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
BR112015022797A2 (pt) 2013-03-13 2017-11-07 Monsanto Technology Llc método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo
EP2971185A4 (en) 2013-03-13 2017-03-08 Monsanto Technology LLC Methods and compositions for weed control
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
UA120426C2 (uk) 2013-11-04 2019-12-10 Монсанто Текнолоджі Елелсі Композиція та спосіб для боротьби з членистоногими паразитами та зараженням шкідниками
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
BR112016016337A2 (pt) 2014-01-15 2017-10-03 Monsanto Technology Llc Composição e métodos para controlar crescimento, desenvolvimento ou a capacidade de reprodução de uma planta, e para sensibilizar uma planta para um herbicida inibidor de epsps
CN110506752B (zh) 2014-04-01 2022-02-18 孟山都技术公司 用于控制虫害的组合物和方法
EP3158067B1 (en) 2014-06-23 2020-08-12 Monsanto Technology LLC Compositions and methods for regulating gene expression via rna interference
WO2015200539A1 (en) 2014-06-25 2015-12-30 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
UA124255C2 (uk) 2015-01-22 2021-08-18 Монсанто Текнолоджі Елелсі Інсектицидна композиція та спосіб боротьби з leptinotarsa
UY36703A (es) 2015-06-02 2016-12-30 Monsanto Technology Llc Composiciones y métodos para la administración de un polinucleótido en una planta
AU2016270913A1 (en) 2015-06-03 2018-01-04 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
EP3408390A4 (en) 2016-01-26 2019-10-09 Monsanto Technology LLC COMPOSITIONS AND METHODS FOR COMBATING INSECTS
CN117677586A (zh) * 2022-06-13 2024-03-08 菲克雷丁·萨欣 镥盐化合物用于抗病毒作用的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501058A (ja) * 1989-12-04 1993-03-04 アイシス・ファーマシューティカルス・インコーポレーテッド 乳頭腫ウイルス属のアンチセンスオリゴヌクレオチド阻害
JP2823959B2 (ja) * 1991-10-24 1998-11-11 アイシス・ファーマシューティカルス・インコーポレーテッド 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
US5684149A (en) * 1993-01-22 1997-11-04 Research Foundation Of State University Of New York Metal complexes for promoting catalytic cleavage of RNA by transesterification
DE4415370A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20030064944A1 (en) * 2001-06-21 2003-04-03 Isis Pharmaceuticals Inc. Antisense modulation of transforming growth factor beta receptor II expression
AU2003241621A1 (en) * 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
WO2003106477A1 (en) * 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US20080009455A9 (en) * 2005-02-24 2008-01-10 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
JP2009535383A (ja) * 2006-05-03 2009-10-01 バルティック テクロノジー デヴェロプメント，リミテッド 強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069551A (zh) * 2014-08-19 2021-07-06 西北大学 蛋白质/寡核苷酸核-壳纳米颗粒治疗剂

Also Published As

Publication number Publication date
WO2009060122A3 (en) 2009-06-25
CA2704549A1 (en) 2009-05-14
JP5710977B2 (ja) 2015-04-30
US20110171287A1 (en) 2011-07-14
EP2212420A2 (en) 2010-08-04
WO2009060122A2 (en) 2009-05-14
BRPI0819191A2 (pt) 2017-03-21
ZA201003234B (en) 2011-06-29
MX2010004983A (es) 2010-07-29
AU2008324066A1 (en) 2009-05-14
JP2011502501A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
JP5710977B2 (ja) 抗ウイルス薬としての修飾塩基を含むオリゴヌクレオチドの使用
EP1532248B1 (en) Modified small interfering rna molecules and methods of use
JP7634542B2 (ja) Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
US20230118138A1 (en) Use of scamp3 inhibitors for treating hepatitis b virus infection
JPWO2004078974A1 (ja) Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
JP2025094072A (ja) Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2023506954A (ja) Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
CN114829601A (zh) Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
WO2009144365A1 (en) Use of oligonucleotides with modified bases as antiviral agents
HK40077333A (en) Use of saraf inhibitors for treating hepatitis b virus infection
HK40078459A (en) Use of scamp3 inhibitors for treating hepatitis b virus infection
HK40078456A (en) Use of sbds inhibitors for treating hepatitis b virus infection
HK40071185A (en) Use of sept9 inhibitors for treating hepatitis b virus infection
JP2013223426A (ja) Ｒｒｍ２のアンタゴニストを有効成分として含有するｃ型肝炎治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110209